
Multi-drug resistant tuberculosis (MDR-TB)
Medical Need announces that the product GranuPAS® has been granted EU marketing authorization by the European Commission on April 7, 2014. The product contains para-aminosalicylic
Medical Need announces that the product GranuPAS® has been granted EU marketing authorization by the European Commission on April 7, 2014. The product contains para-aminosalicylic
Medical Need enters into a collaboration with Atlantic Pharmaceuticals on first-in-class therapy for inflammatory bowel disease Medical Need, Stockholm Sweden and Atlantic Pharmaceuticals Ltd, Cambridge
About para-aminosalicylic acid in gastro-resistant granules Para-aminosalicylic acid is used for the treatment of MDR-TB, as part of an appropriate combination regimen, in adults and
Medical Need gains rights to product for the treatment of progressive multiple sclerosis (MS) Medical Need announced today that it has entered into an exclusive
New EU orphan drug designation for the treatment of Congenital Sucrase-Isomaltase Deficiency Medical Need Europe AB earlier announced that the European Commission has approved the
EU Marketing Authorization for the treatment of Urea Cycle Disorders Medical Need announced today that the European Commission on July 31, 2013, issued a marketing
Medical Need and CTD Holdings enter into a partnership for treatment of Niemann-Pick Type C disease Medical Need today announced that it has entered into
Immedica Pharma AB
Norrtullsgatan 15
113 29 Stockholm
Sweden
E-mail: info@immedica.com
Phone: +46(0)8 533 39 500
© 2019 All rights Reserved. Design by Immedica